Atrial natriuretic peptide protects against histamine-induced endothelial barrier dysfunction in vivo

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 1-8

  Fürst, Robert ^a   Bubik, Martin F ^a   Bihari, Peter ^b   Mayer, Bettina A ^a   Khandoga, Alexander G ^b   Hoffmann, Florian ^a   Rehberg, Markus ^b   Krombach, Fritz ^b   Zahler, Stefan ^a   Vollmar, Angelika M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA CATENIN; F ACTIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; HISTAMINE; MYOSIN LIGHT CHAIN 2; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR C; PROTEIN P120; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL JUNCTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTRIC RESISTANCE; ENDOTHELIAL DYSFUNCTION; HEMATOCRIT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CAPILLARY PERMEABILITY; CELLS, CULTURED; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HEMATOCRIT; HISTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; UMBILICAL VEINS;

EID: 45749087292     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045773     Document Type: Article

References (31)

1. Baez S (1973) An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 5:384-394.
2. Baron DA, Lofton CE, Newman WH, and Currie MG (1989) Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. Proc Natl Acad Sci U S A 86:3394-3398.
3. Fürst R, Brueckl C, Kuebler WM, Zahler S, Krötz F, Görlach A, Vollmar AM, and Kiemer AK (2005) Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96:43-53.
4. Garcia JG, Davis HW, and Patterson CE (1995) Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol 163:510-522.
5. Garcia JG, Schaphorst KL, Shi S, Verin AD, Hart CM, Callahan KS, and Patterson CE (1997) Mechanisms of ionomycin-induced endothelial cell barrier dysfunction. Am J Physiol 273:L172-L184.
6. Hatakeyama T, Pappas PJ, Hobson RW, Boric MP, Sessa WC, and Duran WN (2006) Endothelial nitric oxide synthase regulates microvascular hyperpermeability in vivo. J Physiol 574:275-281.
7. Huxley VH, Tucker VL, Verburg KM, and Freeman RH (1987) Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res 60:304-307.
8. Imamura T, Ohnuma N, Iwasa F, Furuya M, Hayashi Y, Inomata N, Ishihara T, and Noguchi T (1988) Protective effect of alpha-human atrial natriuretic polypeptide (alpha-HANP) on chemical-induced pulmonary edema. Life Sci 42:403-414.
9. Inomata N, Ohnuma N, Furuya M, Hayashi Y, Kanai Y, Ishihara T, Noguchi T, and Matsuo H (1987) Alpha-human atrial natriuretic peptide (alpha-HANP) prevents pulmonary edema induced by arachidonic acid treatment in isolated perfused lung from guinea pig. Jpn J Pharmacol 44:211-214.
10. Irwin DC, Patot MT, Tucker A, and Bowen R (2005a) Neutral endopeptidase null mice are less susceptible to high altitude-induced pulmonary vascular leak. High Alt Med Biol 6:311-319.
11. Irwin DC, Rhodes J, Baker DC, Nelson SE, and Tucker A (2001) Atrial natriuretic peptide blockade exacerbates high altitude pulmonary edema in endotoxin-primed rats. High Alt Med Biol 2:349-360.
12. Irwin DC, Tissot van Patot MC, Tucker A, and Bowen R (2005b) Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am J Physiol Lung Cell Mol Physiol 288:L849-L859.
13. Kiemer AK, Fürst R, and Vollmar AM (2005) Vasoprotective actions of the atrial natriuretic peptide. Curr Med Chem Cardiovasc Hematol Agents 3:11-21.
14. Kiemer AK and Vollmar AM (2001) The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 60 Suppl 3:iii68 -iii70.
15. Kiemer AK, Weber NC, Fürst R, Bildner N, Kulhanek-Heinze S, and Vollmar AM (2002a) Inhibition of P38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-α-induced actin polymerization and endothelial permeability. Circ Res 90:874-881.
16. Kiemer AK, Weber NC, and Vollmar AM (2002b) Induction of IκB: atrial natriuretic peptide as a regulator of the NF-Kb pathway. Biochem Biophys Res Commun 295:1068-1076.
17. Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, and Vollmar AM (2007) Atrial natriuretic peptide, a regulator of nuclear factor-kappab activation in vivo. Endocrinology 148:332-336.
18. Lofton CE, Baron DA, Heffner JE, Currie MG, and Newman WH (1991) Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability. J Mol Cell Cardiol 23:919-927.
19. Mehta D and Malik AB (2006) Signaling mechanisms regulating endothelial permeability. Physiol Rev 86:279-367.
20. Morishita Y, Sano T, Ando K, Saitoh Y, Kase H, Yamada K, and Matsuda Y (1991) Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 176:949-957.
21. Nwariaku FE, Liu Z, Zhu X, Turnage RH, Sarosi GA, and Terada LS (2002) Tyrosine phosphorylation of vascular endothelial cadherin and the regulation of microvascular permeability. Surgery 132:180-185.
22. Ogunrinade O, Kameya GT, and Truskey GA (2002) Effect of fluid shear stress on the permeability of the arterial endothelium. Ann Biomed Eng 30:430-446.
23. Pedram A, Razandi M, and Levin ER (2002) Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J Biol Chem 277:44385-44398.
24. Poredos P (2001) Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost 7:276-280.
25. Potter MD, Barbero S, and Cheresh DA (2005) Tyrosine phosphorylation of VE-cadherin prevents binding of P120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem 280:31906-31912.
26. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, and Kuhn M (2005) Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115:1666-1674.
27. van Buul JD, Anthony EC, Fernandez-Borja M, Burridge K, and Hordijk PL (2005) Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation. J Biol Chem 280:21129-21136.
28. van Nieuw Amerongen GP, and van Hinsbergh VW (2002) Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vascul Pharmacol 39:257-272.
29. Volk T and Kox WJ (2000) Endothelium function in sepsis. Inflamm Res 49:185-198.
30. Wakabayashi G, Ueda M, Aikawa N, Naruse M, and Abe O (1990) Release of ANP and its physiological role in pulmonary injury due to HCl. Am J Physiol 258:R690-R696.
31. Weber NC, Blumenthal SB, Hartung T, Vollmar AM, and Kiemer AK (2003) ANP inhibits TNF-alpha-induced endothelial MCP-1 expression - involvement of p38 MAPK and MKP-1. J Leukoc Biol 74:932-941.